Clinical Trials
81 trialsPROACT
Washington University School of Medicine
Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps
Thomas Jefferson University
A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives
Thomas Jefferson University
Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma
Columbia University
ClaSPd
Weill Medical College of Cornell University
A Phase II Study of Bevacizumab and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma
Hackensack Meridian Health
PD-L1 Peptide Vaccination in High Risk Smoldering Multiple Myeloma
Herlev Hospital
MYMO
Centre Hospitalier Universitaire de Nīmes
AntiCD-66
University of Southampton
Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients
Icahn School of Medicine at Mount Sinai
Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer
M.D. Anderson Cancer Center
DMV
University of California, San Francisco
Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy
Masonic Cancer Center, University of Minnesota
Chloroquine in Combination With VELCADE and Cyclophosphamide for Relapsed and Refractory Multiple Myeloma
NYU Langone Health
T Cells in Predicting Acute Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant
Vanderbilt-Ingram Cancer Center
Ascending Dose and Exploratory Expansion Study of DS-3032b, an Oral MDM2 Inhibitor, in Subjects With Relapsed and/or Refractory Multiple Myeloma
M.D. Anderson Cancer Center
Study of Immune Response Modifier in the Treatment of Hematologic Malignancies
Masonic Cancer Center, University of Minnesota
Sorafenib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Mayo Clinic
Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene
M.D. Anderson Cancer Center
Positron Emission Tomography (PET) Imaging Studies With NIS Reporter
Mayo Clinic
Thalidomide to Overcome Lenalidomide Resistance After Autologous Hematopoietic Stem Cell Transplantation (HCT)
M.D. Anderson Cancer Center
Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation
Barbara Ann Karmanos Cancer Institute
Interferon Alfa and Interleukin-6 in Treating Patients With Recurrent Multiple Myeloma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
PrE1003
PrECOG, LLC.
DexTR
Weill Medical College of Cornell University
Trial of ID-Specific Donor Vaccinated Lymphocyte Infusion for Patients With Myeloma Relapsing or Failing to Achieve a Complete Remission After an Allogenic Transplant
M.D. Anderson Cancer Center
Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma
NYU Langone Health
Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma
UNC Lineberger Comprehensive Cancer Center
Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant
Masonic Cancer Center, University of Minnesota
Pilot Study of Multi-Modality Imaging in Patients With Hematologic Malignancies
Masonic Cancer Center, University of Minnesota
Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases
Masonic Cancer Center, University of Minnesota
Filgrastim Compared With Sargramostim Plus Chemotherapy, Peripheral Stem Cell Transplantation, and Interferon Alfa in Treating Patients With Multiple Myeloma
Masonic Cancer Center, University of Minnesota
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
Masonic Cancer Center, University of Minnesota
CpG 7909 in Treating Patients Who Have Undergone Autologous Stem Cell Transplant
Masonic Cancer Center, University of Minnesota
Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant
Masonic Cancer Center, University of Minnesota
UARK 2003-25: A Study of Intravenous (IV) Busulfan (Busulfex®) in Multiple Myeloma Patients
University of Arkansas
Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer
OHSU Knight Cancer Institute
Oncaspar/Doxil/Decadron in Patients With Refractory Lymphoid Malignancies
Milton S. Hershey Medical Center
Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease
Fred Hutchinson Cancer Center
Busulfan in Multiple Myeloma
University of Iowa
Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant
OHSU Knight Cancer Institute
Blood Samples From Patients on a Clinical Trial to CINV During HSCT
OHSU Knight Cancer Institute
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant
Alliance for Clinical Trials in Oncology
Anti-thymocyte Globulin and Melphalan in Treating Patients With Relapsed Multiple Myeloma
Mayo Clinic
Lactobacillus in Preventing Infection in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Myelodysplastic Syndrome
Rutgers, The State University of New Jersey
2nd Autologous Stem Cell Transplant in Patients With Persistent/Recurrent (AL) Amyloidosis
Boston Medical Center
Revlimid / All-Trans Retinoic Acid (ATRA) / Dexamethasone in Relapsed/Refractory Multiple Myeloma
M.D. Anderson Cancer Center
Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients
University of Utah
506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment
Alliance for Clinical Trials in Oncology
Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL Amyloidosis
M.D. Anderson Cancer Center